Molecular Partners FY 2023 GAAP EPS $(2.13) Misses $(2.00) Estimate, Sales $7.894M Beat $5.333M Estimate
Portfolio Pulse from Benzinga Newsdesk
Molecular Partners (NASDAQ:MOLN) reported FY 2023 GAAP EPS of $(2.13), missing the $(2.00) estimate, but their sales of $7.894M exceeded the $5.333M estimate. This represents a 95.98% decrease in sales compared to the same period last year.
March 14, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Molecular Partners reported a larger than expected loss per share but exceeded sales estimates for FY 2023, with a significant decrease in sales compared to last year.
The miss on the EPS estimate and the significant year-over-year decrease in sales are likely to negatively impact investor sentiment in the short term, despite the beat on sales estimates.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100